TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00489645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo SC during euglycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide
Description: pramlintide SC during eglycemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo during hyperglycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide
Description: pramlintide SC during hyperglycemia
Study: NCT00863798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release 10mg
Description: 10 mg tablet, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release 50 mg
Description: 50 mg tablet, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study: NCT03298529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose solution
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional egg pasta
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with eight egg whites/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with four eggs/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperproteic pasta (with added gluten and albumin)
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta with only four egg whites/kg flour
Description: 12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
Study: NCT02142634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide granules 9 mg
Description: per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: per day
Study: NCT04296422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs or oral contraceptives treatment
Description: Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose acupuncture
Description: Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Description: Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
Study: NCT00980577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NUUS
Description: Sonosite Micro Maxx
Study: NCT03049098

Intervention type: BEHAVIORAL
Intervention: Simulation
Description: A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing

Intervention type: BEHAVIORAL
Intervention: Simulation
Description: A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
Study: NCT03932578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate
Description: Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Patients will receive IV metoclopramide 10 mg in 2 ml
Study: NCT03916822

Intervention type: DIAGNOSTIC_TEST
Intervention: Alloantigen-specific B-cells
Description: Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Alloantigen-specific B-cells
Description: Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Alloantigen-specific B-cells
Description: Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
Study: NCT01982786

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided external beam radiotherapy with or without brachytherapy boost
Description: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided external beam radiotherapy with or without brachytherapy boost
Description: image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy boost
Study: NCT02509312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Study: NCT04492137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cannulation technique
Description: Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed
Study: NCT02646735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Description: Fulvestrant 500mg will be given monthly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane 25 mg
Description: Exemestane 25mg will be given once daily.
Study: NCT03046797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroptic intubation through Boussignac valve opening
Description: After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Fibroptic intubation
Description: After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
Study: NCT02356796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group treatment
Description: Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy treatment
Description: Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
Study: NCT02675803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VAY736 placebo
Description: VAY736 placebo
Study: NCT04735913

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate tablets
Description: Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
Study: NCT03954223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate diet
Description: Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate diet
Description: Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate diet
Description: Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Limited Eating
Description: 16-hour fast/8-hour feed for 3 days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Limited Eating
Description: 16-hour fast/8-hour feed for 3 days per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: CGM (used to monitor adherence and glycemic outcomes without real time feedback)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: CGM (used to monitor adherence and glycemic outcomes without real time feedback)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: CGM (used to monitor adherence and glycemic outcomes without real time feedback)
Study: NCT04476836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy
Description: Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
Study: NCT02483845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Study: NCT05329233

Intervention type: DEVICE
Intervention: Masimo Radical-7 Pulse CO-Oximeter
Description: The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA

Intervention type: DEVICE
Intervention: Masimo Radical-7 Pulse CO-Oximeter
Description: The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA

Intervention type: DEVICE
Intervention: Masimo Radical-7 Pulse CO-Oximeter
Description: The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
Study: NCT05051423

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes.
Study: NCT03927690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LKA651
Description: LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LKA651
Description: LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Study: NCT01850823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone nasal spray
Study: NCT00715637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin and Cytarabine
Description: Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amonafide and Cytarabine
Description: Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
Study: NCT01605656

Intervention type: BEHAVIORAL
Intervention: Cognitive Interview
Description: A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes.
Study: NCT01785147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.4979
Description: BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.4979
Description: BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.4979
Description: BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04137718

Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention

Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention
Study: NCT04853134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide
Description: 200 mg q.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as determined by the PI
Study: NCT01649505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrin sealant (Beriplast P, TISSEEL VH)
Description: Applied topically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast reconstruction
Description: Undergo sharp dissection technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast reconstruction
Description: Undergo electrocoagulation dissection technique
Study: NCT00188825

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Study: NCT01397500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Genotropin administered sc once a day by patient or caregiver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecannoate
Description: Testosterone undecannoate administered twice (6 week Interval) im by investigator.
Study: NCT01579721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Surgery
Description: Single incision laparoscopic surgery for rectal cancer
Study: NCT00610025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
Study: NCT03588819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: 26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
Study: NCT04473053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD139
Description: TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients will receive standard care.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic SARS-CoV-2 VSTs
Description: The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.